Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

(2020) Juan Lantero Rodriguez et al.   ACTA NEUROPATHOLOGICA

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

(2020) Juan Fortea et al.   LANCET

Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study

(2020) Antoinette O’Connor et al.   MOLECULAR PSYCHIATRY

Blood-based molecular biomarkers for Alzheimer’s disease

(2019) Henrik Zetterberg et al.   Molecular Brain

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease

(2019) Carla M. Startin et al.   Alzheimers Research & Therapy

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

(2019) Alberto Lleó et al.   Alzheimers & Dementia

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse

(2019) Daniel Alcolea et al.   Annals of Clinical and Translational Neurology

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

(2018) Michelle M. Mielke et al.   Alzheimers & Dementia

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

(2018) Juan Fortea et al.   LANCET NEUROLOGY

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years

(2018) Rosalyn Hithersay et al.   JAMA Neurology

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

(2017) Harutsugu Tatebe et al.   Molecular Neurodegeneration

Dementia in Down's syndrome

(2016) Clive Ballard et al.   LANCET NEUROLOGY

Age dependence of brain  -amyloid deposition in Down syndrome: An [18F]florbetaben PET study

(2015) D. Jennings et al.   NEUROLOGY

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease

(2014) A. M. Fagan et al.   Science Translational Medicine

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE